As part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative, the trial will study the use of Bristol Myers Squibb/Pfizer’s Eliquis blood thinner in patients discharged from the hospital following a case of moderate-to-severe COVID-19. The other two ACTIV studies involve hospitalized and nonhospitalized COVID-19 adults.
The trials are taking place at more than 100 sites worldwide.
Researchers noticed early in the COVID-19 pandemic that many people who died have blood clots throughout their bodies — clotting that can cause multiple health complications ranging from organ damage to heart attack. The ACTIV-4 trials are meant to answer critical questions about properly use blood thinners or anticoagulants to treat COVID-19 cases.
Filed Under: clinical trials, Drug Discovery, Infectious Disease